Eli Lilly invested in Absci, putting $40 million into the AI startup in a $50 million funding round that centers on a medication designed to stimulate hair growth, with potential additional indications including endometriosis. The investment expands Lilly’s aesthetic and therapeutic ambitions beyond its core metabolic franchises. The deal highlights how large pharma is using early-stage AI-platform partners to accelerate asset discovery and preclinical iteration, while also diversifying into non-traditional growth areas. Absci’s funding also strengthens its ability to support clinical and regulatory preparation for first assets. For the biotech sector, the Absci-Lilly move provides another example of pharma capital targeting AI-first companies with platform leverage—potentially reducing time-to-candidate selection in novel therapeutic areas. Market attention will likely turn to Absci’s lead compound progress, IND-enabling plans, and how hair-growth claims translate into clinical endpoints.